Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008
MALVERN, Pa., Nov. 18 /PRNewswire/ -- Arlington Medical Resources (AMR), a
provider of premier market intelligence for the pharmaceutical and diagnostic
imaging industries, finds that over $10 million of CSL Behring's Privigen was
sold in the U.S. during the third
quarter of 2008. Privigen is the ...
SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
Pivotal Phase III Trial Primary Endpoints Achieved for SCOLR's 12-Hour Ibuprofen
BOTHELL, Wash., Nov. 7 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc.
(Amex: DDD ) today reported financial results for the three and nine months
ended September 30, 2008. The Company...
Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals,
Inc. (Nasdaq: CADX ), a biopharmaceutical company focused on in-licensing,
developing and commercializing proprietary product candidates principally
for use in the hospital setting, today reported financial results for the
CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011-vcMMAE Phase II Trial Results on November 3, 2008
BRANFORD, Conn., Oct. 29 /PRNewswire-FirstCall/ -- CuraGen Corporation
(Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on
oncology, announced today that Company executives will be holding a
conference call and webcast at 11:00 a.m. ET on Monday, November 3, 2008
Physicians Estimate That if Approved, Ceftobiprole Will Steal Nearly a Third of Zyvox's Patient Share in the Treatment of Nosocomial Pneumonia
Most Important Factors Driving Nosocomial Pneumonia Prescribing in Hospitals Are Infectious Disease Consults and ATS/IDSA Guidelines Arlington Medical Resources and Decision Resources Introduce the New Hospital Anti-Infectives Insight Series
MALVERN, Penn. and WALTHAM, Mas...
NewCardio Announces Positive Results From Third Clinical Validation Study
Test validates QTinno(TM) - proves the ability to automatically measure QT intervals in even challenging samples
SANTA CLARA, Calif., Aug. 13 /PRNewswire-FirstCall/ -- NewCardio, Inc.,
(OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today
revealed the resul...
Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
- Company Reports Positive Top-line Results from Second Phase 3 Study of Intermezzo(R) -
PT. RICHMOND, Calif., June 4 /PRNewswire/ -- Transcept Pharmaceuticals,
Inc., a specialty pharmaceutical company deriving significant new patient
benefits from proven CNS drugs, ...
NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
SOPHIA ANTIPOLIS, France, May 28 /PRNewswire-FirstCall/ -- NicOx S.A.
(Euronext Paris: COX) today announced the completion of patient enrollment
in the third
pivotal phase 3 clinical trial for naproxcinod, in patients
with osteoarthritis of the hip (the 303 study). 810 patients have been
NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit
Multiple Clinical Applications for Blood-Derived Stem Cells and Strong Industry Outlook Support NeoStem's Business Model
NEW YORK, Feb. 28 /PRNewswire-FirstCall/ -- NeoStem, Inc. (Amex: NBS ),
which is pioneering the pre-disease collection, processing and long-term
storage of adult...
Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
Enrolling Patients with Urge Incontinence Who Have Failed Alternative Therapies
EAST NORRITON, Pa., Jan. 3 /PRNewswire/ -- Tengion, Inc., a clinical
stage regenerative medicine company focused on the development of
neo-organs and neo-vessels, announced today it i...
GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
ATLANTA, Nov. 15 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC
Bulletin Board: GOVX), an Atlanta-based biotechnology company (the
"Company"), today announced its financial results and provided an
operational update for the quarter ended September 30, 2007. Financial Results for the Quarter...
Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
ROCKVILLE, Md., Nov. 12 /PRNewswire-FirstCall/ -- Novavax Inc. (Nasdaq:
NVAX) today reported financial results for the third
September 30, 2007 and reviewed its recent accomplishments and upcoming
milestones. Novavax reported a net loss of $9.0 million, or the equivalent
Vanda Pharmaceuticals Reports Third Quarter 2007 Results
Submits Iloperidone New Drug Application (NDA); Begins Phase III Chronic
Insomnia Study for VEC-162; Reports Results in VSF-173 Phase II Proof of Concept Trial; Updates Full Year 2007 Financial Guidance
ROCKVILLE, Md., Nov. 8 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals
Genta Incorporated Announces Third Quarter 2007 Financial Results
- New Phase 3 trial of Genasense(R) in melanoma opens to global accrual - Clinical trial opened for G4544 treatment of bone disease - Named-patient/compassionate-use program ships initial supply - Appeal filed to review FDA decision on Genasense in CLL
- Brief high-dose IV infusi...
PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
ANNAPOLIS, Md., Nov. 6 /PRNewswire-FirstCall/ -- PharmAthene (Amex:
PIP), a biodefense company specializing in the development of medical
countermeasures against biological and chemical threats, will webcast its
third quarter 2007 financial results conference call on Tuesday, November
Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
- Conference Call/Webcast to be held today at 10:00 AM EST -
TARRYTOWN, N.Y., Nov. 6 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS ) today announced its financial results for
quarter ended September 30, 2007. Emisphere Technologies, Inc. will host a con...
Pharmacopeia Announces Third Quarter 2007 Financial Results
Pharmacopeia Advances and Expands Internal Pipeline as DARA Program Enters Phase 2 Clinical Development and New SARM Program is Added
PRINCETON, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq:
PCOP) today announced results for the quarter and nine months ended
September 30, 2...
QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
VENLO, The Netherlands, Oct. 30 /PRNewswire-FirstCall/ -- In
conjunction with QIAGEN's Third
Quarter 2007 Earnings release, you are
invited to listen to its conference call which will be broadcast live over
the Internet on Tuesday, November 6, 2007 at 9:30 a.m. EST, with Peer M.
Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
Primary Analysis of Pivotal Trial to Be Available No Later Than July 2008
SAN DIEGO, Oct. 25 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq:
FVRL), a biopharmaceutical company developing patient-specific, active
immunotherapies for the treatment of cancer, announced that an independent
The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
DOYLESTOWN, Penn., Oct. 25 /PRNewswire-FirstCall/ -- The Quigley
Corporation (Nasdaq: QGLY ) today reported net sales of $11.8 million, for
quarter ended September 30, 2007, compared to $11.5 million
reported for the same period in 2006. For the nine-months ended September
Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
SAN DIEGO, Oct. 11 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated
(Nasdaq: GPRO ) announced today that the Company will release its third
quarter 2007 financial results on Tuesday, October 30, 2007 at
approximately 4:00 p.m. Eastern Time (ET). The announcement will be
followed by a conferen...
Biopure Announces 2007 Third Quarter Financial Results
CAMBRIDGE, Mass., Aug. 23 /PRNewswire-FirstCall/ -- Biopure Corporation
(Nasdaq: BPUR ) today announced its financial results for the third
quarter ended July 31, 2007. For the quarter, the company reported a net
loss of $6.4 million, or $0.08 per common share, compared with a net loss...
CeNeRx BioPharma Announces Positive Phase I Results in First Human
Trial of Third Generation RIMA Antidepressant
- Tyrima Demonstrates Good Safety Profile and Excellent
Pharmacokinetic Properties -
RESEARCH TRIANGLE PARK, N.C., March 13, 2007 /PRNewswire/ --
CeNeRx BioPharma, Inc., a clinical stage company developing and
commercializing innovative treatments for diseases of the central
nervous system, today ...
Can-Fite Proceeds with Development of Third Drug; Progress in
Development of CF502 Will Be Presented at the Annual European
Congress of Rheumatology
PETACH TIKVA, Israel--(BUSINESS WIRE)--Jun 14, 2007 - Can-Fite
BioPharma (TASE:CFBI), a biotechnology company traded on the Tel
Aviv Stock Exchange Exchange, proceeds with the development of its
third drug CF502; this is in addition to CF101, which is currently
in clinical trials and CF102, which i...
Neurologix to Present at the Third Annual C.E. Unterberg Towbin
Emerging Growth Conference
FORT LEE, N.J.--(BUSINESS WIRE)--Jul 6, 2007 - Neurologix, Inc.
(OTCBB:NRGX), a biotechnology company engaged in the development of
innovative gene therapies for the brain and central nervous system,
announced today that the company will present at the Third
C.E. Unterberg Towbin Emerging Gr...
Actemra (tocilizumab) Third Phase III Study Results Show
Significant Improvement in Symptoms of Patients with Rheumatoid
- Multinational Phase III Study Meets Primary Endpoint in
Rheumatoid Arthritis Patients Who Failed to Respond to Anti-tumor
Necrosis Factor Treatments -
NUTLEY, N.J., July 10, 2007 /PRNewswire/ -- Roche today
announced that results from the Actemra Radiate (RheumAtoiD
ArthritIs Study in Anti-TNF F...
Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
Colorectal cancer is the fourth most common cancer in men and the third
most common cancer in women worldwide. In 2007, approximately 1.2 million c...ent investigations, litigation and products liability claims. We depend on third
parties for a significant portion of our manufacturing capacity for the sup...
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
...ns, the Company's revenue will decrease when the $50 million upfront payment Isis received from Ortho-McNeil-Janssen in 2007 is fully amortized in the third
quarter of this year.
On a pro forma basis, operating expenses for the three and six months ended June 30, 2009 were...
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
... and the company's position to enter into new strategic collaborations with third
parties. These forward-looking statements involve numerous risks and uncer... have issued may not be enforceable, or intellectual property licenses from third
parties may be required in the future; (iv) the outcome of any future intel...
ARUP Laboratories Applauds FDA's Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer
...stance to Anti-EGFR Therapy ," elaborates on this testing and can be found at www.aruplab.com.
"In the United States, colorectal cancer is the third
most common form of cancer and individuals have a 6 percent lifetime risk of developing this disease," said Executive Vice President of Corporate Comm...
Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
...ucts after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third
parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may ...
Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window
...who would not have been previous candidates for treatment could benefit from therapies that could restore their quality of life."
Stroke is the third
leading cause of death in the United States, Canada, Europe and Japan. According to the American Stroke Association, approximately 800,000 Americans ...
Diabetes Gene Raises Odds of Lower Birth Weight
...ital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking third
in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 430-bed hospital r...
Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms
...ed in the merger agreement, and the potential for loss of key personnel, disruption in key business activities or any impact on our relationships with third
parties as a result of the announcement of the proposed merger; the inherent uncertainty of the timing and success of, and expense associated with, re...
Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
.... Applications will be reviewed in October.
Octapharma AG , the third
largest plasma products manufacturer in the world, launched the grants prog...n and review process.
Octapharma AG is the third
largest plasma products manufacturer in the world and has been committed to...
Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
...ompany's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third
parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and supplie...
Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
...th Lantus, they also reported significantly fewer episodes of confirmed hypoglycemia.
These intent-to-treat results were from DURATION-3, the third
in a series of studies designed to test the superiority of exenatide once weekly, an investigational diabetes therapy, as compared to other diabetes m...
Bionovo's Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
...ns or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third
party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different fr...
Velos, Inc. Releases Software to Support Cancer Centers With New Workflow and Content for NCI Clinical Trials Reporting Program
...los eResearch, empowers customers by giving them ownership and access to functions such as system configuration, data migrations, custom reporting and third
party data submissions. Velos is privately held with headquarters in Fremont, California. For more information, visit www.velos.com .
deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke
...The new SNP is in the ZFHX3 gene on chromosome 16q22, and the more than
of people of European descent who carry one copy are at
approximately 20% g...oncern, our ability to
develop and market diagnostic products, the level of third
reimbursement for our products, risks related to preclinical and clin...